Intuitive Surgical
ISRG
$390.33
-1.06%
Intuitive Surgical Inc. is a global leader in robotic-assisted minimally invasive surgery, developing and marketing the da Vinci surgical system along with its instrumentation, accessories, and services. The company has placed over 10,000 da Vinci systems worldwide, with more than 6,000 in the US, establishing a dominant market position in the surgical robotics space. Currently, the stock is under pressure due to concerns about slowing growth, as management did not raise full-year guidance after a strong Q2, and regulatory scrutiny over a stapler safety issue. Despite these headwinds, the company continues to innovate and expand its installed base, with analysts debating whether the recent pullback presents a buying opportunity or signals a longer-term deceleration.…
ISRG
Intuitive Surgical
$390.33
Related headlines
Investment Opinion: Should I buy ISRG Today?
Based on the analysis, I rate ISRG as a Hold. The company has strong fundamentals, with revenue growth of 22.96% YoY and a dominant market position, but the valuation is stretched (trailing PE 70.8x) and there are near-term headwinds from regulatory concerns and slowing growth guidance. The analyst consensus is Buy with an average target of $478.01, implying 21.2% upside, but the wide range ($324 to $685) reflects uncertainty.
Sign up to view all
ISRG 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While the company's fundamentals are solid, the valuation is stretched and there are near-term risks from regulatory and competitive pressures. The stock is likely to trade in a range, with the base case being the most probable. An upgrade to bullish would occur if revenue growth accelerates and the stapler issue is resolved, while a downgrade to bearish would occur if growth slows significantly or regulatory actions are severe.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $478.01 and implied upside of +22.5% versus the current price.
Average Target
$478.01
0 analysts
Implied Upside
+22.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$324 - $685
Analyst target range
The price target range is $324.00 (low) to $685.00 (high), showing a wide spread of $361, indicating significant uncertainty about the stock's future. The low target implies a 17.9% downside, possibly pricing in regulatory issues or slower growth, while the high target suggests a 73.6% upside, likely assuming successful expansion of the da Vinci system and new product launches. The wide range reflects the market's mixed views on the company's growth prospects and valuation. Recent institutional actions have been mostly reaffirmations of existing ratings, with no major downgrades, suggesting analysts are maintaining their positive stance despite the recent pullback.
Bulls vs Bears: ISRG Investment Factors
Intuitive Surgical presents a classic growth-versus-valuation debate. On the bull side, the company boasts robust revenue growth (22.96% YoY), a dominant market position with over 10,000 installed systems, and high profitability (66.1% gross margin). On the bear side, the stock faces slowing growth guidance, an elevated valuation (trailing PE 70.8x), regulatory concerns, and competitive threats. Currently, the bear case has stronger evidence in the short term, as the stock has underperformed significantly and analysts have not raised targets. The most critical tension is whether the company can sustain its high growth rate to justify its valuation; if growth decelerates further, the stock could see multiple compression, but if it accelerates, the current price may be a bargain.
Bullish
- Robust Revenue Growth: Q1 2026 revenue grew 22.96% YoY to $2.77B, accelerating from 21.1% in Q4 2025 and 18.9% in Q3 2025. This shows strong demand for robotic surgery systems and recurring revenue from instruments and services.
- Dominant Market Position: With over 10,000 da Vinci systems installed globally and 6,000+ in the US, Intuitive has a massive installed base that creates high switching costs and a strong competitive moat against new entrants like Medtronic's Hugo.
- High Profitability: Gross margin is 66.1% and operating margin is 29.3%, with net margin of 28.4%. This demonstrates strong pricing power and operational efficiency, supporting high valuation multiples.
- Strong Balance Sheet: Debt-to-equity is only 0.017, and current ratio is 4.87, indicating minimal leverage and ample liquidity. This financial strength provides flexibility for R&D and potential acquisitions.
Bearish
- Slowing Growth Guidance: Management did not raise full-year guidance after a strong Q2, signaling slower growth ahead. This triggered a 17.3% decline over the past year and a 29.8% YTD drop, underperforming the S&P 500 significantly.
- Elevated Valuation: Trailing PE is 70.8x and forward PE is 32.7x, with a PEG ratio of 3.17. This implies the market expects 116% EPS growth, which may be too optimistic given the maturing installed base and competitive threats.
- Regulatory and Safety Concerns: The FDA flagged a safety concern over Intuitive's stapler, which could lead to reputational damage, potential recalls, or increased regulatory scrutiny. This adds uncertainty to future revenue and could impact trust in the brand.
- Competitive Pressure: Medtronic's Hugo robot received FDA approval, and other competitors are emerging. While Intuitive has a head start, increased competition could pressure pricing and market share in the long term.
ISRG Technical Analysis
ISRG is in a clear downtrend over the past year, with the stock down 17.3% over the last 12 months, significantly underperforming the S&P 500, which gained 20.4% over the same period. The current price of $394.51 sits at 65.3% of its 52-week range (between $328.57 low and $603.88 high), indicating the stock is closer to its lows than highs, reflecting a bearish sentiment. The stock has also declined 29.8% year-to-date, while the S&P 500 is up 13.9%, showing persistent relative weakness.
Beta
1.46
1.46x market volatility
Max Drawdown
-44.0%
Largest decline past year
52-Week Range
$329-$604
Price range past year
Annual Return
-18.7%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | +13.0% | +4.0% |
| 3m | -11.6% | +5.3% |
| 6m | -22.1% | +12.6% |
| 1y | -18.7% | +20.1% |
| ytd | -30.5% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Intuitive Surgical's revenue growth remains robust, with Q1 2026 revenue of $2.77 billion, up 22.96% year-over-year, accelerating from the 21.1% growth in Q4 2025 and 18.9% in Q3 2025. The company's revenue mix is led by Instruments and Accessories at $1.69 billion, followed by Systems at $650.7 million and Services at $433.7 million, indicating a strong recurring revenue base. This growth trajectory suggests continued demand for robotic surgery, though the pace may moderate as the installed base matures.
Quarterly Revenue
$2.8B
2026-03
Revenue YoY Growth
+23.0%
YoY Comparison
Gross Margin
66.1%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Given that ISRG is profitable, the PE ratio is the primary valuation metric. The trailing PE is 70.8x, while the forward PE is 32.7x, implying the market expects significant earnings growth. The gap between trailing and forward PE reflects anticipated EPS growth from $5.57 to $12.07, a 116% increase, which seems aggressive but is supported by the company's strong revenue growth and margin expansion. The PEG ratio of 3.17 suggests the stock is expensive relative to its growth rate, but this is typical for a market leader with a dominant position.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~85x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
49.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate. Intuitive has a very low debt-to-equity ratio of 0.017 and a strong current ratio of 4.87, indicating low financial leverage and ample liquidity. However, the company's high valuation (trailing PE 70.8x) leaves little room for error; any earnings miss or guidance cut could trigger a sharp de-rating. Revenue concentration is a risk, as the company relies heavily on the da Vinci system and its associated instruments; any disruption in the installed base or procedure volumes could impact recurring revenue. Additionally, the company's free cash flow is strong at $2.83B TTM, but the high PCF ratio of 66.7 suggests the market is paying a premium for that cash flow, which could compress if growth slows.